In 2019, Wang and his colleagues, through analyzing medical data of 47,721 patients with various cancer types with POLE/POLD1 mutations, proposed that POLE/POLD1 mutations are promising potential predictive biomarkers for positive ICI outcomes (66). This evidence concerns the gene POLD1 and cancer.